IP Verse

Combination Immunotherapy Of Antigen-Recognizing Receptors And Hematopoietic Cells For The Treatment Of Diseases - EP3025719

The patent EP3025719 was granted to Miltenyi Biotec on Sep 26, 2018. The application was originally filed on Nov 25, 2015 under application number EP15196309A. The patent is currently recorded with a legal status of "Revoked".

EP3025719

MILTENYI BIOTEC
Application Number
EP15196309A
Filing Date
Nov 25, 2015
Status
Revoked
Sep 1, 2023
Grant Date
Sep 26, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HOFFMANN EITLEJun 26, 2019HOFFMANN EITLEADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP2711418
DESCRIPTIONUS2012309091
DESCRIPTIONWO2012012667
DESCRIPTIONWO2014059173
DESCRIPTIONWO2014127261
DESCRIPTIONWO2015017214
DESCRIPTIONWO2015090229
DESCRIPTIONWO2015142661
DESCRIPTIONWO2015150771
OPPOSITIONWO2012012667
OPPOSITIONWO2017066760
OPPOSITIONWO2017079400

Non-Patent Literature (NPL) Citations (40) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BRENTJENS, R.J.; DAVILA, M.L.; RIVIERE, I.; PARK, J.; WANG, X.; COWELL, L.G.; BARTIDO, S.; STEFANSKI, J.; TAYLOR, C.; OLSZEWSKA, M, "CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia", SCIENCE TRANSLATIONAL MEDICINE, (2013), vol. 5, page 177RA138-
DESCRIPTION- IMMUNOLOGY, (2006), vol. 117, pages 145 - 155-
DESCRIPTION- LAMERS, C.H.; SLEIJFER, S.; VAN STEENBERGEN, S.; VAN ELZAKKER, P.; VAN KRIMPEN, B.; GROOT, C.; VULTO, A.; DEN BAKKER, M.; OOSTERWI, "Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity", MOLECULAR THERAPY, (2013), vol. 21, pages 904 - 912, XP002755666-
DESCRIPTION- SCHENDEL, D.J.; FRANKENBERGER, B., "Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity", ONCOIMMUNOLOGY, (2013), vol. 2, page E22410-
DESCRIPTION- TANIGUCHI, R.T.; GUZIOR, D.; KUMAR, V., "2B4 inhibits NK-cell fratricide", BLOOD, (2007), vol. 110, pages 2020 - 2023-
DESCRIPTION- WU ET AL., SCIENCE, (2015), vol. 350, pages 293 - 303-
DESCRIPTION- ZEBEDEE, S.L.; BARRITT, D.S.; RASCHKE, W.C., "Comparison of Mouse Ly5a and Ly5b Leucocyte Common Antigen Alleles", DEVELOPMENTAL IMMUNOLOGY, (1991), vol. 1, pages 243 - 254-
DESCRIPTION- ANURATHAPAN, U.; LEEN, A.M.; BRENNER, M.K.; VERA, J.F., "Engineered T cells for cancer treatment", CYTOTHERAPY, (2014), vol. 16, doi:doi:10.1016/j.jcyt.2013.10.002, pages 713 - 733, XP055465916
DESCRIPTION- MORGAN, R.A.; YANG, J.C.; KITANO, M.; DUDLEY, M.E.; LAURENCOT, C.M.; ROSENBERG, S.A., "Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2", MOLECULAR THERAPY, (2010), vol. 18, doi:doi:10.1038/mt.2010.24, pages 843 - 851, XP055023624
DESCRIPTION- HOLT, N.; WANG, J.; KIM, K.; FRIEDMAN, G.; WANG, X.; TAUPIN, V.; CROOKS, G.M.; KOHN, D.B.; GREGORY, P.D.; HOLMES, M.C. ET AL., "Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo", NATURE BIOTECHNOLOGY, (2010), vol. 28, doi:doi:10.1038/nbt.1663, pages 839 - 847, XP055101952
DESCRIPTION- PORTER, D.L.; LEVINE, B.L.; KALOS, M.; BAGG, A.; JUNE, C.H, "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia", THE NEW ENGLAND JOURNAL OF MEDICINE, (2011), vol. 365, doi:doi:10.1056/NEJMoa1103849, pages 725 - 733, XP055247863
DESCRIPTION- GRUPP, S.A.; KALOS, M.; BARRETT, D.; APLENC, R.; PORTER, D.L.; RHEINGOLD, S.R.; TEACHEY, D.T.; CHEW, A.; HAUCK, B.; WRIGHT, J.F. E, "Chimeric antigen receptor-modified T cells for acute lymphoid leukemia", THE NEW ENGLAND JOURNAL OF MEDICINE, (2013), vol. 368, doi:doi:10.1056/NEJMoa1215134, pages 1509 - 1518, XP055169041
DESCRIPTION- LEISEGANG, M.; WILDE, S.; SPRANGER, S.; MILOSEVIC, S.; FRANKENBERGER, B.; UCKERT, W.; SCHENDEL, D.J., "MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors", THE JOURNAL OF CLINICAL INVESTIGATION, (2010), vol. 120, doi:doi:10.1172/JCI43437, pages 3869 - 3877, XP055103910
DESCRIPTION- GILL, S.; TASIAN, S.K.; RUELLA, M.; SHESTOVA, 0.; LI, Y.; PORTER, D.L.; CARROLL, M.; DANET-DESNOYERS, G.; SCHOLLER, J.; GRUPP, S.A, "Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.", BLOOD, (2014), vol. 123, doi:doi:10.1182/blood-2013-09-529537, pages 2343 - 2354, XP002748004
OPPOSITION- KUIJPERS et al., "CD 20 deficiency in humans results in impaired T cell -independent antibody responses", J Clin Invest, (20100000), vol. 120, no. 1, pages 214 - 222, XP055618336-
OPPOSITION- MARELLI-BERG et al., "An immunologist's guide to CD 31 function in T-cells", J Cell Sci, (20130000), vol. 126, pages 2343 - 2352, XP055618344-
OPPOSITION- ROBERTS et al., "CD 45-deficient severe combined immunodeficiency caused by uniparental disomy", PNAS, (20120626), vol. 109, no. 26, pages 10456 - 10461, XP055618331-
OPPOSITION- Schendel et al., "Limitations for TCR gene therapy by MHC-restricted fracticide and TCR-mediated hematopoietic stem cell technology", Oncolmmunology, (20130100), vol. 2, no. 1, page 322410, XP055618305-
OPPOSITION- BELICHA-VILLANUEVA et al., "What is the role of alternate splicing in antigen presentation by major histocompatibility complex class I molecules", Immunol Res, (20100000), vol. 46, no. 1-3, pages 32 - 44, XP055618317
OPPOSITION- FALKENBURG et al., "T cell therapy in allogeneic stem cell transplantation", Biol Blood Marrow Transplant, (20080100), vol. 14, no. 1, doi:doi:10.1016/j.bbmt.2007.10.022, pages 136 - 141, XP025761633
OPPOSITION- ANURATHAPAN et al., "Engineered T cells for cancer treatment", Cytotherapy, (20140600), vol. 16, no. 6, doi:doi:10.1016/j.jcyt.2013.10.002, pages 713 - 733, XP055465916
OPPOSITION- MANDAL et al., "Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9", Cell Stem Cell, (20141106), vol. 15, doi:doi:10.1016/j.stem.2014.10.004, pages 643 - 652, XP055544679
OPPOSITION- CHO et al., "Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease", Nature Biotechnology, (20130129), vol. 31, no. 3, pages 230 - 232, XP002699850
OPPOSITION- URNOV et al., "Genome editing with engineered zinc finger nucleases", Nature Reviews Genetics, (20100000), vol. 11, no. 9, doi:10.1038/nrg2842, pages 636 - 646, XP055198280
OPPOSITION- BUBIEN et al., "Transfection of the CD 20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes", J Cell Biol, (19930600), vol. 121, no. 5, doi:doi:10.1083/jcb.121.5.1121, pages 1121 - 1132, XP002319729
OPPOSITION- ZERNICH et al., "Natural HLA Class I Polymorphism Controls the Pathway of Antigen Presentation and Susceptibility to Viral Evasion", J Exp Med., (20040000), vol. 200, no. 1, pages 13 - 24, XP055618322
OPPOSITION- KEBRIAEI et al., "Infusing CD -19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem- cell transplantation for advanced B- lymphoid malignancies", Human Gene Therapy, (20120500), vol. 23, doi:doi:10.1089/hum.2011.167, pages 444 - 450, XP055130799
OPPOSITION- CRADICK et al., "CRISPR/Cas9 systems targeting beta-globin and CCR5 genes have substantial off-target activity", Nucleic Acids Research, vol. 41, no. 20, doi:10.1093/nar/gkt714, (20130811), pages 9584 - 9592, XP055186069
OPPOSITION- DAVILA et al., "Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia", Sci TransI Med, (20140000), vol. 6, no. 224, doi:doi:10.1126/scitranslmed.3008226, page 224ra25, XP055234425
OPPOSITION- KOLB, "Graft-versus-leukemia effects of transplantation and donor lymphocytes", Blood, (20080000), vol. 112, no. 12, pages 4371 - 4383, XP055618309
OPPOSITION- SHONO et al., "Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation", Blood, (20100000), vol. 115, no. 26, pages 5401 - 5411, XP055618314
OPPOSITION- UKENA et al., "Human regulatory T cells in allogeneic stem cell transplantation", Blood, (20110000), vol. 118, no. 13, doi:doi:10.1182/blood-2011-05-352708, pages e 82 - 92, XP055233559
OPPOSITION- GILL et al., "Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells", Blood, (20140410), vol. 123, no. 15, doi:doi:10.1182/blood-2013-09-529537, pages 2343 - 2354, XP002748004
OPPOSITION- BERGOM et al., "An alternatively spliced isoform of PECAM-1 is expressed at high levels in human and murine tissues, and suggests a novel role for the C-terminus of PECAM-1 in cytoprotective signalling", J Cell Sci, (20080000), vol. 121, pages 1235 - 1242, XP055618340
OPPOSITION- KOO et al., "Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9", Mol Cells, vol. 38, no. 6, doi:10.14348/molcells.2015.0103, (20150519), pages 475 - 481, XP055372009
OPPOSITION- HENIG et al., "Hematopoietic Stem Cell Transplantation - 50 Years of Evolution and Future perspectives", Rambam Maimonides Med J, (20041000), vol. 5, no. 4, pages 1 - 15, XP055618295
SEARCH- CHRISTIAN S HINRICHS ET AL, "Reassessing target antigens for adoptive T-cell therapy", NATURE BIOTECHNOLOGY, US, (20131020), vol. 31, no. 11, doi:10.1038/nbt.2725, ISSN 1087-0156, pages 999 - 1008, XP055243629 [Y] 1-10 * abstract *
SEARCH- RICHARD A. MORGAN ET AL, "Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma", HUMAN GENE THERAPY, (20121001), vol. 23, no. 10, doi:10.1089/hum.2012.041, ISSN 1043-0342, pages 1043 - 1053, XP055123969 [Y] 1-9 * abstract *
SEARCH- SATIRO NAKAMURA DE OLIVEIRA ET AL, "Modification of Hematopoietic Stem/Progenitor Cells with CD19-Specific Chimeric Antigen Receptors as a Novel Approach for Cancer Immunotherapy", HUMAN GENE THERAPY, US, (20131001), vol. 24, no. 10, doi:10.1089/hum.2012.202, ISSN 1043-0342, pages 824 - 839, XP055244062 [Y] 1-9 * abstract *
SEARCH- SUSUMU UCHIYAMA ET AL, "Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope", CANCER SCIENCE, JP, (20100101), vol. 101, no. 1, doi:10.1111/j.1349-7006.2009.01392.x, ISSN 1347-9032, pages 201 - 209, XP055244043 [Y] 10 * figure 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents